Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Dr Elez on the Rationale for Evaluating QOL Outcomes With ICI Doublets in mCRC

September 30th 2025

Elena Élez, MD, PhD, discusses quality of life outcomes with combination checkpoint blockade in patients with microsatellite instability-high mCRC.

Dr Shields on the Evolving Role of Prophylactic Cranial Irradiation in SCLC

September 30th 2025

Misty D. Shields, MD, PhD, discusses the modern role for prophylactic cranial irradiation in extensive-stage SCLC management.

Dr Mauro on How Genetic Alterations Impact TKI Decisions in CML

September 30th 2025

Michael J. Mauro, MD, discusses how genetic alterations, such as BCR::ABL mutations, inform treatment decisions in CML.

Orphan Drug Designation Sought for Crofelemer to Manage Treatment-Related Diarrhea in Breast Cancer With Brain Metastases

September 29th 2025

Crofelemer may receive ODD for diarrhea treatment in patients with breast cancer and brain metastases receiving targeted therapy with/without chemotherapy.

Dr Mulherin on Using AI to Address NGS Testing Barriers in Oncology Practice

September 28th 2025

Brian P. Mulherin, MD, discusses using AI tools to improve the implementation of NGS in community oncology practice.

Dr Wilfong on the Potential Use of AI Prediction Models to Improve Palliative Care in Oncology

September 28th 2025

Lalan Wilfong, MD, expands on the value of AI prediction models for consensus on patient prognosis and better end-of-life care in oncology.

Dr Flora on the Potential Role of AI in Clinical Trial Screening and Design for Oncology

September 28th 2025

Douglas Flora, MD, LSSBB, discusses how the use of artificial intelligence tools could improve patient screening and drug development in oncology.

ASCENT-GYN-01 Trial of Sacituzumab Govitecan Aims to Validate Clinical Utility of TROP2 ADCs in Pretreated Endometrial Cancer

September 26th 2025

Ramez N. Eskander, MD, discusses prior data supporting the ongoing investigation of sacituzumab govitecan as monotherapy in endometrial cancer.

Dr Mascarenhas on the IMpact-MF Trial of Imetelstat in R/R Myelofibrosis

September 26th 2025

John Mascarenhas, MD, outlines the ongoing phase 3 IMpact-MF trial, evaluating imetelstat in relapsed/refractory myelofibrosis.

Dr Vojnic on Vorasidenib in Grade 2 IDH1/2-Mutated Glioma

September 26th 2025

Morana Vojnic, MD, MBA, discusses vorasidenib in grade 2 IDH1/2-mutated glioma.

Dr Sherman on Advances in Surgical Brain Tumor Management

September 26th 2025

Jonathan H. Sherman, MD, FAANS, FCNS, FACS, discusses notable advances in the surgical management of patients with brain tumors.

Sunvozertinib Approval Fills Treatment Gap in Pretreated EGFR Exon 20–Mutant NSCLC

September 26th 2025

Lyudmila A. Bazhenova, MD, discusses the FDA approval of sunvozertinib (Zegfrovy) in patients with EGFR exon 20–mutant non–small cell lung cancer.

Dr Ghia on the Implications of Data From CAPTIVATE for Fixed-Duration Ibrutinib Plus Venetoclax in CLL/SLL

September 26th 2025

Paolo Ghia, MD, provided insights into the significance of updated data from the final analysis of the phase 2 CAPTIVATE study in CLL/SLL.

Dr Mehnert on Next Steps for the Evaluation of Quadruplet Therapy in Advanced Melanoma

September 26th 2025

Janice M. Mehnert, MD, discusses the ongoing investigation of sarilumab plus ipilimumab, nivolumab, and relatlimab in unresectable stage III/IV melanoma.

Dr Nathan on the Mechanism of Action of Roginolisib in Metastatic Uveal Melanoma

September 26th 2025

Paul Nathan, MBBS, PhD, MRCP, describes the mechanism of action of roginolisib and its ongoing evaluation in metastatic uveal melanoma.

Breast Cancer Experts: Key ADC Developments and CDK 4/6 Inhibitor Updates Set to Dominate ESMO 2025

September 25th 2025

Ahead of the 2025 ESMO Congress, breast cancer experts share the most anticipated research being presented during the meeting.

Dr Raab on Teclistamab-Based Regimens in Newly Diagnosed Multiple Myeloma

September 24th 2025

Marc S. Raab, MD, discusses teclistamab for the treatment of patients with newly diagnosed multiple myeloma.

SCOPE Score Validated as Predictive Tool for Outcomes With BCMA CAR T-Cell Therapy in R/R Multiple Myeloma

September 24th 2025

The SCOPE score was predictive of response, toxicity, and survival outcomes in patients with relapsed/refractory myeloma receiving BCMA CAR T-cell therapy.

Advancements in Prostate Cancer Imaging, Minimally Invasive Approaches Require Cohesive Screening Recommendations to Optimize Patient Outcomes

September 24th 2025

Paul Gellhaus, MD, spotlights key technological advancements and the need for consensus on PSA screening guidance during prostate cancer awareness month.

Dr Dotan on Gemcitabine and Nab-Paclitaxel in Treatment-Naive, Older Pancreatic Cancer

September 23rd 2025

Efrat Dotan, MD, discusses gemcitabine and nab-paclitaxel in treatment-naive, older patients with pancreatic cancer.